Group 1 - The medical sector showed strong performance with the largest medical ETF (512170) initially rising over 1% and maintaining positive momentum, outperforming the broader market [1] - Over 1.15 billion CNY of net subscriptions were recorded for the medical ETF, indicating strong investor interest [1] - The ETF has a total scale of 27.7 billion CNY, making it the largest in the medical and healthcare category [3] Group 2 - Huatai Medical reported an expected revenue of 2.584 billion CNY for 2025, representing a year-on-year increase of 25%, with net profit projected at 821 million CNY, up 22% [3] - Other companies within the medical ETF, such as United Imaging and Yirui Technology, are also expected to see net profit growth exceeding 40% [3] - The medical ETF consists of over 50% medical device weight and more than 25% CXO content, covering 12 AI medical and brain-machine interface concept stocks [3] Group 3 - The performance of constituent stocks within the ETF varied, with Huatai Medical leading the gains, rising nearly 7%, while major stocks like Mindray and United Imaging saw declines of nearly 1% [2][3]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of over 1.15 billion yuan in recent trading sessions [1][5]. Group 1: ETF Performance - The healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1]. - As of February 24, 2026, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year growth of 25%, with a net profit of 821 million yuan, up 22% [3][4]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3]. Group 3: Market Trends - The healthcare sector is characterized by a mix of rising and falling stocks, with Huatai Medical leading gains by rising nearly 7% after a strong earnings report, while major stocks like Mindray and United Imaging saw declines of nearly 1% [1][3].

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].

（文章来源：证券日报） 证券日报网讯 2月26日，锦波生物发布公告称，公司于近日获得马来西亚主管当局颁发的一项D类医疗 器械注册证，医疗器械名称：重组Ⅲ型人源化胶原蛋白冻干纤维。 ...

证券代码：920982 证券简称：锦波生物 公告编号：2026-008 山西锦波生物医药股份有限公司 关于获得境外医疗器械注册证的公告 注册编号：GD2591526-225199 医疗器械分类：D类 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别 及连带法律责任。 一、基本情况 山西锦波生物医药股份有限公司（以下简称"公司"）于近日获得马来 西亚主管当局颁发的一项D类医疗器械注册证，具体情况如下： 二、医疗器械注册证主要内容 医疗器械名称：重组Ⅲ型人源化胶原蛋白冻干纤维 品牌名称：AYOUTH 规格：2mg/瓶，4mg/瓶，6mg/瓶，8mg/瓶，10mg/瓶，12mg/瓶，16mg/ 瓶，20mg/瓶，24mg/瓶 医疗器械所有人名称：山西锦波生物医药股份有限公司 医疗器械所有人地址：山西综改示范区太原唐槐园区锦波街18号 三、对公司的影响 公司重组Ⅲ型人源化胶原蛋白冻干纤维在马来西亚获批上市，是我国高 端植入型医疗器械产品在国际市场上的又一重要成果，推动了我国原创核心 技术的出海。该产品的获批，有利于公司进一步拓展海 ...

证券研究报告·行业点评报告 2026 年 2 月 26 日 江海证券研究发展部 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -2.51 -5.22 -14.9 绝对收益 -2.41 0.62 3.69 数据来源：聚源 注：相对收益与沪深 300 相比 1. 江海证券-行业深度报告-美容护理行 业：专业皮肤护理行业研究-巨子生物、敷 尔佳、创尔生物 – 2026.01.14 2. 江海证券-行业点评报告-美容护理行 业：创健医疗重组胶原蛋白植入剂获批， 林清轩通过港交所上市聆讯 – 2025.12.30 3. 江海证券-行业点评报告-美容护理行 业："双 11"天猫抖音美妆榜出炉，巨子 生物重组 I 型胶原蛋白冻干纤维获批 – 2025.10.27 执业证书编号：S1410525120001 消费行业研究组 分析师：黄燕芝 2025 年，珀莱雅稳居淘宝天猫化妆品 榜首，韩束蝉联抖音化妆品榜首 事件： 美容护理行业 投资要点： 江海证券有限公司及其关联机构在法律许可的情况下可能与本报告所分析的企业存在业务关系，并且继续寻求发展这些关系。因此，投资者应当考虑到本公司可能存在影响本报告客观性的 ...

截至2026年2月26日 09:56，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 4.59%，爱博医疗上涨2.03%，锦波生物上涨0.40%；惠泰医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近3天获得连续资金净流入，最高单日获得617.32万元净流入， 合计"吸金"1269.71万元，日均净流入达423.24万元。（数据来源：Wind） 消息面上，2026年，中国创新药对外BD交易（商务拓展交易）持续升温、势头强劲。医药魔方 NextPharma数据库显示，截至2月25日，年内中国创新药已发生44起对外授权（license-out）交易事件， 首付款约为31.23亿美元，总金额达532.76亿美元。 江海证券指出，2026年中国创新药BD呈现三大转型：技术输出联合产品授权、平台化合作、全球并跑 创新。建议关注小核酸（递送技术/慢病管线）、肿瘤免疫（双抗/ADC联用）、代谢疾病（GLP-1改良 品种/MASH肝靶向siRNA）、CGT（体内基因编辑/通用型CAR-T）等核心赛道，重点评估平台造血能 力（如年输出管线数）、临床里 ...

山西汾酒以2094.68亿元的市值继续"一骑绝尘"，牢牢占据山西板块年度市值榜首；大秦铁路以1039.59亿元位列第二，上述也是山西唯二千亿级企业。 山西汾酒于1994年1月在上海证券交易所上市，是中国白酒第一股，亦山西第一股。山西汾酒控股股东汾酒集团为山西省18家省属国企之一。 目前，山西汾酒业绩表现已跻身行业前三，形成"茅五汾"三足鼎立的局面。山西汾酒2025年三季报显示，其前三季度实现收入329.2亿元，同比增长 5.0%；实现归母净利润114.1亿元。 此外，山西还有12家上市公司总市值在百亿级别，其中山西焦煤、潞安环能、永泰能源均超过300亿元。 2025年A股市场呈现"震荡上行、结构分化、科技引领、制度护航"的特征，这些特点也同样映射在山西板块。 截至2025年12月31日，A股全年收涨18.41%，涨超600点，创10年新高；山西板块全年涨幅27.41%，跑赢大盘，41家A股上市公司中东杰智能大涨 186.7%，涨幅位居第一。 随着股价提升，不少公司市值也出现新突破。不过，晋融社梳理发现，41只晋股市值居前的大多集中于传统产业，而股价涨幅居前的则多聚集于新兴产 业，且多家布局涉足机器人相关产业。 ...

智通财经APP获悉，国金证券发布研报称，奢侈品、高端香化、高端零售业绩修复加速，高净值人群消 费恢复或是高端消费改善的主要原因。该行认为，当前中国高端消费筑底效应已经展现，短期内高端消 费修复需依靠高净值人群的财富效应与针对中产的政策刺激。中长期看，需关注收入和就业的系统性改 善、房地产的企稳回升，以及财富效应从高净值人群向中产的扩散节奏。高端消费实际需求改善+供给 相对稀缺+政策效果强，重点推荐免税、黄金珠宝行业。 国金证券主要观点如下： 免税：低基数，强政策红利，高端消费修复，有望带动免税行业重回增长 免税是进口化妆品、奢侈品等高档消费品流通的重要渠道，将极大受益于高端消费恢复。海南自由贸易 港正式启动封关，有望对海南本地以及全国的免税业务产生明显的影响，叠加高端消费复苏趋势持续演 绎，影响逻辑有望超预期。此外，日本旅游热度下滑后，海南成为新热门目的地。去哪儿旅行、携程等 平台数据显示，截至2月初，春节假期目的地为海南的日均机票订单量同比增长超45%。 中国中免：公司基本面回暖，从内需看，高端消费的恢复是免税行业复苏的基础，免税行业存在整体性 机会；从外需看，入境游客的消费潜力，并未被市场充分认识，预期中 ...

Core Viewpoint - The article emphasizes that despite the prevailing narrative of economic hardship, certain industries are thriving and generating significant profits, particularly in the context of Japan's "lost 30 years" and the evolving consumer behavior in China [3][4]. Group 1: Emerging Business Opportunities - The article identifies eight key industries that are experiencing growth, highlighting that a low-desire society does not equate to a lack of opportunities [4]. - The concept of consumption upgrading and demand migration is presented as the largest business opportunity [5]. Group 2: Second-Hand Economy - In the context of reduced spending on luxury goods, the second-hand economy is flourishing, with companies like "大黑屋" in Japan and "红布林" and "胖虎" in China seeing substantial revenue increases [6][7]. - The article notes that platforms like "闲鱼" and "转转" are experiencing significant user engagement and transaction volume growth [9][10]. Group 3: Pet Economy - The pet economy is highlighted as a growing sector, with young consumers spending on premium pet products despite having fewer children [12]. - Companies like "中宠" and various pet brands are witnessing strong sales growth, indicating a shift in consumer spending towards pet care [13][14][15]. Group 4: Adult Care Products - The adult diaper market in Japan has surpassed $10 billion, showcasing the potential of the aging population as a significant economic driver [18][19]. - The article suggests that aging should be viewed as an opportunity rather than a burden, contributing to a multi-trillion dollar "sunset economy" [19]. Group 5: Health Food and Beverages - The rise in health consciousness and demographic changes are driving demand for sugar-free beverages and functional foods, with brands like "东方树叶" and "简醇" gaining traction in China [21][22]. Group 6: Beauty and Aesthetics - The beauty industry continues to thrive, with products like collagen supplements and home beauty devices achieving significant sales, indicating a persistent consumer desire for beauty enhancements [23][24][26]. Group 7: Outdoor and Leisure Activities - The outdoor equipment market is growing, with brands like "凯乐石" and "骆驼" benefiting from increased consumer interest in outdoor activities [29][31]. - The article notes that even in economic downturns, consumers are willing to invest in experiences and leisure [32]. Group 8: Convenience and Time-Saving Products - The "lazy economy" is emerging, with increased demand for frozen foods and smart home appliances that save time, reflecting a shift in consumer priorities towards convenience [39][40]. - The article posits that in a low-desire economy, time-saving solutions may hold greater commercial value than cost-saving measures [42].